Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

MD simulations of SARS-CoV-2 Spike Protein under static electric fields

Domaine:

healthcare

Type de record:

dataset
Créateur:
Arbeitman, Claudia R.Rojas, PabloOjeda-May, PedroGarcia, Martin E.
Éditeur:
Zenodo
Hôte:avatar

This dataset contains trajectories corresponding to all-atom MD simulations of segments of the SARS-CoV-2 Spike Protein, and in-silico mutations, under the influence of moderate external electric fields. The final structures of some of the simulations were used to perform in-silico docking with ACE2 receptor to evaluate the effect of comformational changes (docking was perform with PyDOCK).

The file trajectories_6vsb_dt1ns.zip contains trajectories of simulations that were performed on a segment of the Protein Data Bank ID 6VSB comprising RBD, SD1 and SD2. The file trajectories_6m0j_dt1ns.zip correspond to the RBD in Protein Data Bank ID 6M0J. The file trajectories_in-silico_mutations_dt1ns.zip correspond to simulations performed on in-silico generated mutations following the mutations corresponding to WHO Variants of Concern UK, South Africa and Brazil. In all cases, simulations were performed at different electric field intensities ranging between 104 V/m and 107 V/m, with an extra short simulation under very high intensity (109 V/m). The file docked_structures_6m0j.zip contains the 100 best scored docked structures for each case as the output of PyDOCK.

Trajectories are stored in GROMACS compressed trajectory file format (.xtc), downsampled to a 1ns timestep. Individual trajectories length are between 300 nanoseconds and 1 microsecond. In-silico docked structures are in PDB format. See linked preprint for more details.

Calculations were performed at Lichtenberg High Performance Computer of the TU Darmstadt, the High Performance Center North (HPC2N) at SNIC, and at local dedicated workstations of our group. Supported by the PhosMOrg (P/1082 232) research unit of the University of Kassel, and Joachim Herz Foundation through its Add-on Fellowship for Interdisciplinary Life Science. Acknowledgements to the Argentinian AntiCovid Consortium (Argentina) for valuable discussions, and Dr. Bernd Bauerhenne for his help with computing resources.

Visit

doi.org

Tags

SARS-CoV-2spike proteincovid19covid-19COVID-19sars-cov-2SARS-COV-2

Licenses

info:eu-repo/semantics/openAccessCreative Commons Attribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/legalcode

Similaires

Human SARS CoV-2 spike protein mutations in West AfricaMolecular evolution and adaptation of SARS-CoV-2 omicron XBB sub-lineage Spike protein under African selection pressureCirculating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!TaqMan SARS-CoV-2 mutation panel and spike gene sequencing for the detection of SARS-COV-2 VOCsTable_2_SAS: A Platform of Spike Antigenicity for SARS-CoV-2.xlsxTable_3_SAS: A Platform of Spike Antigenicity for SARS-CoV-2.xlsx

Human SARS CoV-2 spike protein mutations in West Africa

Background: The COVID-19 pandemic was caused by the severe acute respiratory syndrome coronavirus-2

Molecular evolution and adaptation of SARS-CoV-2 omicron XBB sub-lineage Spike protein under African selection pressure

Abstract The SARS-CoV-2 Omicron variant of concern (VOC) has multiple mutations in

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!

Abstract Objective Herd immunity is achieved when in a populati

TaqMan SARS-CoV-2 mutation panel and spike gene sequencing for the detection of SARS-COV-2 VOCs

Ti is raw data of the comparison between two tests for the screecring od SARS-COV-2 variant of Conce

Table_2_SAS: A Platform of Spike Antigenicity for SARS-CoV-2.xlsx

Since the outbreak of SARS-CoV-2, antigenicity concerns continue to linger with emerging mutants.

Table_3_SAS: A Platform of Spike Antigenicity for SARS-CoV-2.xlsx

Since the outbreak of SARS-CoV-2, antigenicity concerns continue to linger with emerging mutants.